Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.29 USD | -1.42% | -2.61% | -.--% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 6.73M | Capitalization | 390M |
---|---|---|---|---|---|
Net income 2024 * | -52M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 58.1 x |
P/E ratio 2024 * |
-5.46
x | P/E ratio 2025 * |
-6.38
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.17% |
1 day | -1.42% | ||
1 week | -2.61% | ||
1 month | -3.29% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 15.29 | -1.42% | 123,978 |
24-05-30 | 15.51 | +0.13% | 151,624 |
24-05-29 | 15.49 | +0.65% | 252,140 |
24-05-28 | 15.39 | -1.97% | 155,392 |
24-05-24 | 15.7 | -0.13% | 214,482 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 390M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- LENZ Stock